AI assistant
Boundless Bio, Inc. — Director's Dealing 2024
Apr 4, 2024
34838_dirs_2024-04-04_29df3018-7a01-499d-ba78-b5e835758ab9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Boundless Bio, Inc. (BOLD)
CIK: 0001782303
Period of Report: 2024-04-02
Reporting Person: ARCH Venture Fund IX, L.P. (N/A)
Reporting Person: ARCH Venture Fund IX Overage, L.P. (N/A)
Reporting Person: ARCH Venture Fund X Overage, L.P. (N/A)
Reporting Person: ARCH Venture Partners IX, L.P. (N/A)
Reporting Person: ARCH Venture Partners IX Overage, L.P. (N/A)
Reporting Person: ARCH Venture Partners X Overage, L.P. (N/A)
Reporting Person: ARCH Venture Partners IX, LLC (N/A)
Reporting Person: ARCH Venture Partners X, LLC (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-04-02 | Common Stock | C | 589743 | — | Acquired | 617092 | Indirect |
| 2024-04-02 | Common Stock | C | 787545 | — | Acquired | 828570 | Indirect |
| 2024-04-02 | Common Stock | C | 1048433 | — | Acquired | 1048433 | Indirect |
| 2024-04-02 | Common Stock | P | 66667 | $16.00 | Acquired | 683759 | Indirect |
| 2024-04-02 | Common Stock | P | 133333 | $16.00 | Acquired | 1181766 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-04-02 | Series A Convertible Preferred Stock | $ | C | 424908 | Disposed | Common Stock (424908) | Indirect | |
| 2024-04-02 | Series A Convertible Preferred Stock | $ | C | 586080 | Disposed | Common Stock (586080) | Indirect | |
| 2024-04-02 | Series A Convertible Preferred Stock | $ | C | 454212 | Disposed | Common Stock (454212) | Indirect | |
| 2024-04-02 | Series B Convertible Preferred Stock | $ | C | 227920 | Disposed | Common Stock (227920) | Indirect | |
| 2024-04-02 | Series C Convertible Preferred Stock | $ | C | 164835 | Disposed | Common Stock (164835) | Indirect | |
| 2024-04-02 | Series C Convertible Preferred Stock | $ | C | 201465 | Disposed | Common Stock (201465) | Indirect | |
| 2024-04-02 | Series C Convertible Preferred Stock | $ | C | 366301 | Disposed | Common Stock (366301) | Indirect |
Footnotes
F1: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering.
F2: Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX.
F3: Represents shares held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage). ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage.
F4: ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell, Robert Nelsen and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein, if any.
F5: Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.
F6: ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of AVP X Overage LP. Keith Crandell, Robert Nelsen and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X Overage, AVP X LLC may be deemed to beneficially own the shares held by ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage. AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any.
F7: Represents shares purchased by ARCH IX in the Issuer's initial public offering.
F8: Represents shares purchased by ARCH X Overage in the Issuer's initial public offering.